FDA-EMA-CIOMS AI in Pharmacovigilance Principles 2026

What FDA-EMA-CIOMS AI in Pharmacovigilance Principles 2026 requires

Joint principles and CIOMS WG XIV guidance emphasize human oversight, bias mitigation, and validation of AI for signal detection and adverse event processing.

Pillar: Medical & Healthcare · Authority: FDA, EMA, CIOMS · Version: 1.0.0 · Last updated: 2026-05-22

Primary source: https://cioms.ch/

SHA-256 integrity: 619df454bc859f6ff87b9c0120ce9ea85a08402fa2a5bd890fd6660e24babd11

Primary Citations — 5 traced to source

• FDA Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products
• EMA Guideline on Good Pharmacovigilance Practices

+ 3 more citations (full bibliography, deterministic workflow, actionable schema and crosswalks) included in the vault unlock — $0.01 via Skyfire / L402 / Direct Base USDC.

Access

• Discovery (free): /api/v1/nodes/fda-ema-ai-pv-2026.json — 6-field metadata
• Vault (full node): /api/v1/vault/nodes/fda-ema-ai-pv-2026.json — full 13-key payload, $0.01 USDC (L402/Skyfire/Direct Base)
• Canonical URL: https://bidda.com/intelligence/fda-ema-ai-pv-2026
• Back to registry: Browse all 10,090 compliance nodes